Cyclopharm
Cyclopharm is a global radiopharmaceutical company focused on lung imaging solutions. Their flagship product, Technegas, is used for pulmonary embolism diagnosis and other lung conditions. The company aims to advance nuclear pulmonology imaging through innovation and a commitment to superior patient care.
Short position
Cyclopharm (ASX:CYC) has 0.00% of its shares on issue reported as short positions as of 28 Sept 2026, or about 343 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.19% in August 2025. CYC is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Cyclopharm (CYC) financials
Results, ratios and statements
Latest result
12 months to 30 Jun 2026 (TTM Jun 26) vs TTM Jun 25, figures in AUD, the reporting currency
- Revenue
- $17.7Mvs n/a (TTM Jun 25)
- Yahoo Finance, as at 29 Sep 2026
- NPAT
- −$18.3Mvs n/a (TTM Jun 25)
- Yahoo Finance, as at 29 Sep 2026
- EPS (diluted)
- −$0.16vs −$0.12 (TTM Jun 25)
- Yahoo Finance, as at 29 Sep 2026
- Rev YoY
- −39.5%FY
- EPS YoY
- n/aTTM
Key ratios
12 months to 30 Jun 2026 (TTM); balance sheet at 31 Dec 2025, 6 months before; prices to 9 Oct 2026
- Gross margin
- 15.4%
- Operating margin
- −195.0%
- Net margin
- −103.6%
- FCF margin
- −110.5%
- ROE
- −52.5%
- ROA
- −33.9%
- FCF conversion
- n/a
- Net cash (excl. leases)
- $6.6M
- Net debt / EBITDA
- n/a
- Current ratio
- 2.5×
- Interest cover
- −610.4×
- Cash dividends paid / net profit
- n/a
- Market cap
- $51.1M
- P/E
- n/a
- P/B
- 1.9×
Ratios use the reporting currency (AUD); market cap is in AUD. Source: Yahoo Finance, as at 29 Sep 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | TTM Jun 26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Revenue | $17.7M | $16.7M | $27.6M | $26.3M | $23.2M |
| Gross profit | $2.7M | $2.2M | $17.9M | $16.1M | $15.8M |
| Operating income | −$34.5M | −$33.8M | −$14.5M | −$10.0M | −$7.6M |
| EBITDA | −$17.0M | −$16.0M | −$11.6M | −$3.2M | −$5.0M |
| EBIT | −$18.6M | −$17.8M | −$13.0M | −$4.2M | −$6.0M |
| Interest expense | $56.5K | $48.4K | $36.2K | $23.9K | $67.4K |
| Pretax income | −$18.7M | −$17.9M | −$13.1M | −$4.2M | −$6.0M |
| Tax | −$366.3K | −$636.8K | $126.2K | $511.1K | $581.7K |
| NPAT | −$18.3M | −$17.2M | −$13.2M | −$4.7M | −$6.6M |
| Net interest income | −$407.5K | −$324.1K | $350.6K | $273.2K | −$156.2K |
| EPS basic | −$0.16 | −$0.16 | −$0.13 | −$0.051 | −$0.072 |
| EPS diluted | −$0.16 | −$0.16 | −$0.13 | −$0.051 | −$0.072 |
| Shares | n/a | 111.1M | 111.1M | 94.1M | 93.1M |
Financial reports
The company's own filings, newest first
- Half Yearly Report and AccountsHalf Year Results24 Aug 2026via asx_announcements
- Annual Report to shareholdersAnnual Report27 Mar 2026via asx_announcements
- Preliminary Final ReportAnnual Results25 Feb 2026via asx_announcements
- Corporate governance statementFinancial Report31 Dec 2025via crawler
- Corporate governance policyFinancial Report31 Dec 2025via crawler
- 2025 Half-year Results Webinar PresentationHalf Year Results2 Sep 2025via asx_announcements
- Half Yearly Report and AccountsHalf Year Results27 Aug 2025via asx_announcements
- Annual Report to shareholdersAnnual Report27 Mar 2025via asx_announcements
- Preliminary Final ReportAnnual Results25 Feb 2025via asx_announcements
- Remuneration Committee CharterFinancial Report31 Dec 2024via crawler
Showing 10 of 20 reports